Efficacy subgroup analyses in different tumor types.

<p><b>Abbreviations:</b> PFS: progression free survival; OS: overall survival; ORR: overall response rate; HR: hazard ratio; RR: relative risk; BV: bevacizumab; NSCLC: non-small cell lung cancer.</p><p>Efficacy subgroup analyses in different tumor types.</p

Meta-regression analyses.

<p><b>Abbreviations:</b> PFS: progression free survival; OS: overall survival; ORR: overall response rate; BV: bevacizumab.</p><p>Meta-regression analyses.</p

Efficacy subgroup analyses in all trials combined.

<p><b>Abbreviations:</b> PFS: progression free survival; OS: overall survival; ORR: overall response rate; HR: hazard ratio; RR: relative risk; BV: bevacizumab.</p><p>Efficacy subgroup analyses in all trials combined.</p

BV efficacy assessment in trials included in the meta-analysis.

<p><b>Abbreviations:</b> PFS: progression free survival; OS: overall survival; ORR: overall response rate; HR: hazard ratio; RR: relative risk; BV: bevacizumab; NSCLC: non-small cell lung cancer.</p><p>BV efficacy assessment in trials included in the meta-analysis.</p

Meta-analysis of the log hazard ratios of progression free survival comparing bevacizumab and standard therapy in all trials combined.

<p>Meta-analysis of the log hazard ratios of progression free survival comparing bevacizumab and standard therapy in all trials combined.</p

Characteristics of trials included in the meta-analysis.

<p><b>Abbreviations:</b> RCTs: randomized control trials; BV: bevacizumab; MCRC: metastatic colorectal cancer; GC: gastric cancer; MPC: metastatic pancreatic cancer; RCC: renal carcinoma cancer; NSCLC: non-small-cell lung carcinoma; MBC: metastatic breast cancer; AM: advanced mesothelioma; PC: prostate cancer; MC: melanoma carcinoma; OC: ovarian cancer; CC: cervical cancer; RFL: Relapsed Follicular Lymphoma, A: Double-blinded- placebo and active treatment control, B: Placebo and active treatment control, C: Active treatment control.</p><p>Characteristics of trials included in the meta-analysis.</p

Safety assessment of ADRs with BV in all trials combined.

<p><b>Abbreviation:</b> ADRs: adverse drug reactions; RR: relative risk; BV: bevacizumab.</p><p>*Cardiac events including: left ventricular (LV) dysfunction and congestive heart failure.</p><p>**Pulmonary events including: embolism, dyspnea, pneumonitis and hemorrhages.</p><p>Safety assessment of ADRs with BV in all trials combined.</p

Meta-analysis of the risk ratios of overall response rate comparing bevacizumab and standard therapy in all trials combined.

<p>Meta-analysis of the risk ratios of overall response rate comparing bevacizumab and standard therapy in all trials combined.</p

Funnel plots for efficacy assessment in all trials combined.

<p>Funnel plots for efficacy assessment in all trials combined.</p

Meta-analysis of the logs hazard ratios of overall survival comparing bevacizumab and standard therapy in all trials combined.

<p>Meta-analysis of the logs hazard ratios of overall survival comparing bevacizumab and standard therapy in all trials combined.</p